低剂量维奈克拉单药治疗携带t(11;14)的浆细胞恶性肿瘤
该研究评估低剂量维奈克拉(400 mg每日)单药治疗25例携带t(11;14)的多发性骨髓瘤和AL淀粉样变性患者的安全性和疗效。部分缓解及以上率为44%,AL淀粉样变性缓解率71%、骨髓瘤33%,缓解者BCL2/MCL1和BCL2/BCL-XL比值显著更高。
要点
- 维奈克拉单药在t(11;14)浆细胞肿瘤中安全性可控,总体缓解率44%。
- AL淀粉样变性缓解率71%,多发性骨髓瘤33%。
- BCL2/MCL1和BCL2/BCL-XL高比值与缓解显著相关。
核心结论
- 低剂量维奈克拉单药在携带t(11;14)的浆细胞恶性肿瘤中安全性可控且疗效可观,AL淀粉样变性缓解率高于骨髓瘤。
研究设计与样本
- 研究纳入25例携带t(11;14)的多发性骨髓瘤和AL淀粉样变性患者接受维奈克拉400 mg每日治疗,评估安全性和疗效。
- 另用非维奈克拉治疗组样本(包括非t(11;14)诊断27例、t(11;14)诊断17例、t(11;14)复发7例、超二倍体6例、超二倍体+t(11;14) 6例)进行RNA测序和qPCR验证。
主要发现
- 11例(44%)达到部分缓解或更好。
- 缓解者BCL2/MCL1比值(p=0.031)和BCL2/BCL-XL比值(p=0.021)显著更高,与测量时间无关。
- 单药维奈克拉缓解率在AL淀粉样变性为71%,在多发性骨髓瘤为33%。
- 免疫组化有助于预测治疗结局。
临床怎么用
- 对携带t(11;14)的浆细胞肿瘤患者,可考虑维奈克拉单药治疗并监测安全性。
- 治疗前可通过免疫组化检测BCL2家族成员表达,BCL2/MCL1和BCL2/BCL-XL高比值可能预测缓解。
- AL淀粉样变性患者缓解率较高,多发性骨髓瘤患者缓解率相对较低。
局限性
- 研究样本量较小(25例治疗组),需更大规模研究验证。
- IRF5基序富集提示的耐药机制需进一步功能验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Approximately 20% of newly diagnosed multiple myeloma (NDMM) patients harbor t(11;14), a marker of inferior prognosis, resulting in up-regulation of CCND1. These patients respond to BCL2 inhibitor experimental drug venetoclax. Furthermore, t(11;14) is reported to be associated with increased BCL2/MCL1 ratio. We investigated the use of venetoclax (400 mg daily) in a cohort of 25 multiple myeloma (MM) and AL-amyloidosis patients harboring t(11;14) and assessed safety and efficacy. Efficacy was assessed by response rate (RR) and time on treatment. Furthermore, immunohistochemistry (IHC), for BCL2 family member expression was assessed at diagnosis and relapse in the venetoclax-treated group and analyzed for correlation with clinical RR. Additionally, patient material from venetoclax non-treated group including non-t(11;14) diagnosis (n = 27), t(11;14) diagnosis (n = 17), t(11;14) relapse (n = 7), hyperdiploidy (n = 6) and hyperdiploidy + t(11;14) (n = 6) was used for RNA sequencing (RNASeq) and validation by qPCR. Venetoclax treatment in t(11;14) patients demonstrated manageable safety and promising efficacy. Partial responses or better were observed in eleven patients (44%). Responding patients had significantly higher BCL2/MCL1 (p = 0.031) as well as BCL2/BCL-XL (p = 0.021) ratio, regardless of time of measurement before venetoclax treatment. Furthermore, an IRF5 motif was enriched (p < .001) in the downregulated genes in t(11;14) relapses vs diagnoses. The RR with single agent venetoclax was 71% in AL-amyloidosis and 33% in MM, and IHC proved useful in prediction of treatment outcome. We could also demonstrate possible resistance mechanisms of t(11;14), downregulation of IRF5 targeted genes, which can be exploited for therapeutic advantages.
引用
- Nahi H, Kashif M, Klimkowska M, et al. Low dose venetoclax as a single agent treatment of plasma cell malignancies harboring t(11;14). Am J Hematol. 2021. PMID: 33901326. doi:10.1002/ajh.26207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。